10779/rcsi.10778090.v1
Grainne Cousins
Grainne
Cousins
Conor Teljeur
Conor
Teljeur
Nicola Motterlini
Nicola
Motterlini
Colin McCown
Colin
McCown
Borislav D. Dimitrov
Borislav D.
Dimitrov
Tom Fahey
Tom
Fahey
Risk of drug related mortality during periods of transition in methadone maintenance treatment: a cohort study
Royal College of Surgeons in Ireland
2019
Adolescent
Adult
Cohort Studies
Databases
Factual
Female
Humans
Lung Diseases
Male
Medical Records
Methadone
Middle Aged
Opiate Substitution Treatment
Opioid-Related Disorders
Patient Dropouts
Prescriptions
Risk
Time Factors
Young Adult
Family Care
2019-11-22 16:00:25
Journal contribution
https://repository.rcsi.com/articles/journal_contribution/Risk_of_drug_related_mortality_during_periods_of_transition_in_methadone_maintenance_treatment_a_cohort_study/10778090
<p>This study aims to identify periods of elevated risk of drug related mortality during methadone maintenance treatment (MMT) in primary care using a cohort of 3,162 Scottish drug users between January 1993 and February 2004. Deaths occuring during treatment or within 3 days after last methadone prescription expired were considered as cases “on treatment”. Fatalities occuring 4 days or more after leaving treatment were cases “off treatment”. 64 drug related deaths were identified. The greatest risk of drug related death was in the first 2 weeks of treatment (Adjusted hazard ratio 2.60, 95% CI 1.03 to 6.56). Risk of drug related death was lower after the first 30 days following treatment cessation, relative to the first 30 days off treatment. History of psychiatric admission was associated with increased risk of drug related death in treatment. Increasing numbers of treatment episodes and urine testing were protective. History of psychiatric admission, increasing numbers of urine tests and co-prescriptions of benzodiazepines increased the risk of mortality out of treatment. The risk of drug related mortality in MMT is elevated during periods of treatment transition, specifically treatment intitiation and the first 30 days following treatment drop-out or discharge.</p>